IMVT vs JNJ
IMVT: Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | IMVT | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $39.89 | $261.81 | |
| Market cap as of 2026-08-11 | $8.2B | $630.9B | |
| P/E as of 2026-08-11 | n/a | 29.81 | |
| PEG as of 2026-08-11 | n/a | 3.39 | |
| Net margin as of 2026-08-11 | n/a | +21.5% | |
| Gross margin as of 2026-08-11 | n/a | +68.0% | |
| Operating margin as of 2026-08-11 | n/a | +25.7% | |
| ROE as of 2026-08-11 | -69.6% | +25.7% | JNJ higher |
| ROA as of 2026-08-11 | -62.5% | +10.6% | JNJ higher |
| Debt / equity as of 2026-08-11 | 0.00 | 0.58 | IMVT lower |
| Revenue growth (YoY) as of 2026-08-11 | n/a | +8.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +6.2% | |
| Dividend yield as of 2026-08-11 | n/a | +2.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-11 | 0.81 | 0.20 | |
| 1-year return as of 2026-08-10 close | +158.0% | +51.0% | IMVT higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.